Prevalence and risk factors of Helicobacter pylori infection in Korea: Nationwide multicenter study over 13 years

BMC Gastroenterology

Hyun Chae Jung⁶  Joo Sung Kim⁶  Young-Eun Joo⁸  Jeong Eun Shin³  Geom Seog Seo⁵  Gwang Ho Baik⁹  Heung Up Kim²  Jeong Yoon Yim¹  Min Jung Park¹  Jung Mook Kang¹  Gwang Ha Kim⁷  Nayoung Kim⁶  Jin-Won Kwon⁴  Seon Hee Lim¹ 

[1] Seoul National University Hospital, Healthcare System Gangnam Center, Healthcare Research Institute, Seoul, Korea;Department of Internal Medicine, School of Medicine, Jeju National University, Jeju, Korea;Department of Internal medicine, Dankook University College of Medicine, Chonan, Korea;College of Pharmacy, Kyungpook National University, Daegu, Korea;Department of Internal Medicine, Wonkwang University Hospital, Iksan, Korea;Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea;Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea;Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea;Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea

关键词: Cohort;    Epidemiology;    Seroprevalence;    Helicobacter pylori;   

Others  :  857875
DOI  :  10.1186/1471-230X-13-104

 received in 2013-01-14, accepted in 2013-06-21,  发布年份 2013

【 摘 要 】

Background

The aim of this study was to evaluate the time trend of seropositivity of Helicobacter pylori (H. pylori) over the period of 13 years in an asymptomatic Korean population, and investigate associated risk factors.

Methods

This cross-sectional nationwide multicentre study surveyed anti-H. pylori IgG antibodies in 19,272 health check-up subjects (aged [greater than and equal to]16 years) in 2011. Risk factors for H. pylori infection were investigated using logistic regression. Seropositivity in asymptomatic subjects without H. pylori eradication was compared between the years 1998 and 2005. Birth cohort effects were also evaluated.

Results

After exclusion of subjects with a history of H. pylori eradication therapy (n = 3,712, 19.3%) and gastric symptoms (n = 4,764, 24.7%), the seroprevalence of H. pylori infection was 54.4% in 10,796 subjects. This was significantly lower than the seroprevalence of 59.6% in 2005 and that of 66.9% in 1998, and this decrease of seropositivity of H. pylori became widespread across all ages and in most areas of the country. This decreasing trend could be explained by cohort analysis. All younger birth cohorts had a lower seroprevalence of H. pylori than older birth cohorts at the same age. Decreased seroprevalence within the same birth cohorts also accounted for this phenomenon. Clinical risk factors of H. pylori infection were higher cholesterol level ([greater than and equal to] 240 mg/dl) (OR = 1.33; 95% CI = 1.14-1.54), male gender, older age, low income, and residence in a rural area.

Conclusions

A decreasing trend of H. pylori seroprevalence due to a birth cohort effect requires further studies on its related human host factors as well as socio-economic and hygienic factors. In addition, the relationship between H. pylori infection and high cholesterol level needs more investigation regarding underlying pathogenesis.

【 授权许可】

   
2013 Lim et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Egan BJ, Holmes K, O'Connor HJ, O'Morain CA: Helicobacter pylori gastritis, the unifying concept for gastric diseases. Helicobacter 2007, 12(Suppl 2):39-44.
• [2]Parsonnet J: The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995, 9(Suppl 2):45-51.
• [3]Roosendaal R, Kuipers EJ, Buitenwerf J, Meuwissen SG, van Kamp GJ, Vandenbroucke-Grauls CM: Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 1997, 92:1480-1482.
• [4]Taylor DN, Blaser MJ: The epidemiology of Helicobacter pylori infection. Epidemiol Rev 1991, 13:42-59.
• [5]Graham DY, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Adam E: Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991, 100:1495-1501.
• [6]van Zanten SJ V, Pollak PT, Best LM, Bezanson GS, Marrie T: Increasing prevalence of Helicobacter pylori infection with age: continuous risk of infection in adults rather than cohort effect. J Infect Dis 1994, 169:434-437.
• [7]Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA: The cohort effect and Helicobacter pylori. J Infect Dis 1993, 168:219-221.
• [8]Kosunen TU, Aromaa A, Knekt P, Salomaa A, Rautelin H, Lohi P, Heinonen OP: Helicobacter antibodies in 1973 and 1994 in the adult population of Vammala, Finland. Epidemiol Infect 1997, 119:29-34.
• [9]Yim JY, Kim N, Choi SH, Kim YS, Cho KR, Kim SS, Seo KS, Kim HU, Baik GH, Sin CS, Cho SH, Oh BH: Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007, 12:333-340.
• [10]Kim JH, Kim HY, Kim N, Kim SW, Kim JG, Kim JJ, Roe IH SJK, Sim JG, Ahn H, Yoon BC, Lee SW, Lee YC, Chung IS, Jung HY, Hong WS, Choi KW: Seroepidemiological study of Helicobacter pylori infection in asymptomatic people in South Korea. J Gastroenterol Hepatol 2001, 16:969-975.
• [11]Kim SY, Ahn JS, Ha YJ, Doh HJ, Jang MH, Chung SI, Park HJ: Serodiagnosis of Helicobacter pylori infection in Korean patients using enzyme-linked immunosorbent assay. J Immunoassay 1998, 19:251-270.
• [12]Kwon JW, Song YM, Sung J, Sohn Y, Cho SI: Varying patterns of BMI increase in sex and birth cohorts of Korean adults. Obesity (Silver Spring) 2007, 15:277-282.
• [13]Shiota S, Murakami K, Fujioka T, Yamaoka Y: Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective. Expert Rev Gastroenterol Hepatol 2010, 4:149-156.
• [14]Malaty HM, El-Kasabany A, Graham DY, Miller CC, Reddy SG, Srinivasan SR, Yamaoka Y, Berenson GS: Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet 2002, 359:931-935.
• [15]Kim N, Lim SH, Lee KH, Kim JM, Cho SI, Jung HC, Song IS: Seroconversion of Helicobacter pylori in Korean male employees. Scand J Gastroenterol 2005, 40:1021-1027.
• [16]Perez-Perez GI, Rothenbacher D, Brenner H: Epidemiology of Helicobacter pylori infection. Helicobacter 2004, 9(Suppl 1):1-6.
• [17]The EUROGAST Study Group: Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut 1993, 34:1672-1676.
• [18]Moayyedi P, Axon AT, Feltbower R, Duffett S, Crocombe W, Braunholtz D, Richards IDG, Dowell AC, Forman D: Relation of adult lifestyle and socioeconomic factors to the prevalence of Helicobacter pylori infection. Int J Epidemiol 2002, 31:624-631.
• [19]Danesh J, Peto R: Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998, 316:1130-1132.
• [20]Oshima T, Ozono R, Yano Y, Oishi Y, Teragawa H, Higashi Y, Yoshizumi M, Kambe M: Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol 2005, 45:1219-1222.
• [21]Paximadas S, Pagoni ST, Kosmidis M, Tsarouchas X, Christou M, Chatziantonakis N, Papachilleos P: The lipid profile in adults with negative or positive antibody Helicobacter pylori [abstract]. Atherosclerosis supplement 2005, 6:74.
• [22]Kucukazman M, Yavuz B, Sacikara M, Asilturk Z, Ata N, Ertugrul DT, Yalcin AA, Yenigum EC, Kizilca G, Okten H, Akin KO, Nazligul Y: The relationship between updated Sydney System score and LDL cholesterol levels in patients infected with Helicobacter pylori. Dig Dis Sci 2009, 54:604-607.
• [23]Laurila A, Bloigu A, Nayha S, Hassi H, Leinonen M, Saikku P: Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis 1999, 142:207-210.
• [24]Majka J, Rog T, Konturek PC, Konturek SJ, Bielanski W, Kowalsky M, Szczudlik A: Influence of chronic Helicobacter pylori infection on ischemic cerebral stroke risk factors. Med Sci Moni 2002, 8:CR675-CR684.
• [25]Gallin JI, Kaye D, O'Leary WM: Serum lipids in infection. N Engl J Med 1969, 281:1081-1086.
• [26]Grunfeld C, Gulli R, Moser AH, Gavin LA, Feingold KR: Effect of tumor necrosis factor administration in vivo on lipoprotein lipase activity in various tissues of the rat. J Lipid Res 1989, 30:579-585.
• [27]Memon RA, Grunfeld C, Moser AH, Feingold KR: Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 1993, 132:2246-2253.